Efficacy and safety of more intensive lowering of LDL cholesterol [1]

The Lancet

Volumn 377, Issue 9767, 2011, Pages 715-

  Bonovas, Stefanos ^a,b   Nikolopoulos, Georgios ^b   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CARDIOVASCULAR RISK; LETTER; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RISK FACTOR; AGE; BLOOD; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; HUMAN; INCIDENCE; NEOPLASM; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT;

AGE FACTORS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; META-ANALYSIS AS TOPIC; NEOPLASMS; ODDS RATIO; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 79952046739     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60262-6     Document Type: Letter

References (2)

1. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
2. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 2007; 176: 649-54. (Pubitemid 46426061)